ABSTRACT
It has previously been reported that the Ley prosthesis, a 0.5-mm-thick titanium alloy plate designed for reconstruction and stabilization of the unstable sternotomy, leads to shorter hospital stay and reduces the need for further surgical procedures in patients with postoperative mediastinitis after open heart surgery. We report our initial experience with the Ley prosthesis in patients with chronic aseptic sternotomy dehiscence. The study included 6 male patients (age 42-80 years) with opiate-derivate-dependent intractable pain and significantly reduced quality of life caused by noninfected sternal pseudoarthrosis and unstable sternotomy with large sternal bone tissue deficit. Four of the patients had undergone various surgical fixation procedures 8 days to 12 months after the primary operation. The patients were treated with reconstruction and stabilization of the sternum with the Ley prosthesis 10 to 40 months after the primary operation. In 1 patient bone transplantation was used. No immediate peri- or postoperative complications were observed, and all patients were discharged 4 to 11 days after surgery. One patient who received a bone transplant developed wound infection, and the prosthesis was removed 5 weeks after implantation. At 6-month follow-up all sternotomies were found stable, and patients reported that pain had decreased and quality of life was significantly improved. Our results demonstrate that the Ley prosthesis can be safely and efficiently used for the reconstruction and stabilization of the sternum in patients with intractable pain caused by noninfected postoperative sternal dehiscence and large sternal bone tissue deficit.
Subject(s)
Cardiac Surgical Procedures/adverse effects , Plastic Surgery Procedures , Postoperative Complications , Pseudarthrosis/etiology , Sternum/surgery , Adult , Aged , Aged, 80 and over , Chronic Disease , Humans , Male , Middle Aged , Prosthesis Implantation , Retrospective Studies , Sternum/injuries , Time FactorsABSTRACT
Statins reduce mortality in patients with coronary heart disease (CHD). An antiarrhythmic effect of statins has been suggested and reported as a possible contributing mechanism. The aim of this study was to examine whether atorvastatin had any effect on heart rate variability (HRV), an important predictor of sudden cardiac death. Eighty patients previously treated with coronary artery bypass grafting (CABG) were studied. The study was designed as a randomized, placebo-controlled, double blinded crossover study. The patients were randomized in two groups, and were treated with 80 mg atorvastatin or placebo for 6 weeks before crossing over to the opposite treatment for another 6 weeks. There was no washout between treatments. Twenty-four-hour Holter recording and plasma lipids and lipoprotein measurements were performed at baseline and after each 6-week period. There was no change in HRV indices after treatment with 80 mg atorvastatin for 6 weeks. A significant reduction in total cholesterol (46%, p
